Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMA-676 in AML First Relapse
NCT00003131Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 1997
- Primary completion
- Feb 2002
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by Pfizer. Started Feb 1997; status: completed.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003131.